Missense variants in CFTR nucleotide-binding domains predict quantitative phenotypes associated with cystic fibrosis disease severity.
暂无分享,去创建一个
Rachel Karchin | David L Masica | R. Karchin | D. Masica | G. Cutting | P. Sosnay | K. Raraigh | Garry R Cutting | Patrick R Sosnay | Karen S Raraigh
[1] J. Riordan,et al. Purification and Crystallization of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)* , 2004, Journal of Biological Chemistry.
[2] C. Pepine,et al. Coronary angiography: is it time to reassess? , 2013, Circulation.
[3] J. Riordan,et al. CFTR function and prospects for therapy. , 2008, Annual review of biochemistry.
[4] F. Collins,et al. The path to personalized medicine. , 2010, The New England journal of medicine.
[5] J. Hull,et al. Contribution of genetic factors other than CFTR to disease severity in cystic fibrosis , 1998, Thorax.
[6] G. Thaker,et al. Psychosis endophenotypes in schizophrenia and bipolar disorder. , 2007, Schizophrenia bulletin.
[7] Paola Vergani,et al. CFTR channel opening by ATP-driven tight dimerization of its nucleotide-binding domains , 2005, Nature.
[8] Ben Lehner. Genotype to phenotype: lessons from model organisms for human genetics , 2013, Nature Reviews Genetics.
[9] S. Tavtigian,et al. In silico analysis of missense substitutions using sequence‐alignment based methods , 2008, Human mutation.
[10] M. Vihinen,et al. Performance of mutation pathogenicity prediction methods on missense variants , 2011, Human mutation.
[11] George P Patrinos,et al. Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene , 2013, Nature Genetics.
[12] Lisa M Yerian,et al. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease , 2006, Hepatology.
[13] Adam Kiezun,et al. Computational and statistical approaches to analyzing variants identified by exome sequencing , 2011, Genome Biology.
[14] Peter T Nelson,et al. Clinicopathologic Correlations in a Large Alzheimer Disease Center Autopsy Cohort: Neuritic Plaques and Neurofibrillary Tangles "Do Count" When Staging Disease Severity , 2007, Journal of neuropathology and experimental neurology.
[15] Marek Kimmel,et al. Prediction of missense mutation functionality depends on both the algorithm and sequence alignment employed , 2011, Human mutation.
[16] Melissa S. Cline,et al. Using bioinformatics to predict the functional impact of SNVs , 2011, Bioinform..
[17] Tyrone D. Cannon,et al. Endophenotypes in the genetic analyses of mental disorders. , 2006, Annual review of clinical psychology.
[18] Michael Krawczak,et al. Where genotype is not predictive of phenotype: towards an understanding of the molecular basis of reduced penetrance in human inherited disease , 2013, Human Genetics.
[19] Weimin Sun,et al. Extensive sequencing of the cystic fibrosis transmembrane regulator gene: Assay validation and unexpected benefits of developing a comprehensive test , 2003, Genetics in Medicine.
[20] Fernando A Bozza,et al. Cytokine profiles as markers of disease severity in sepsis: a multiplex analysis , 2007, Critical care.
[21] Rachel Karchin,et al. Phenotype‐optimized sequence ensembles substantially improve prediction of disease‐causing mutation in cystic fibrosis , 2012, Human mutation.
[22] L. Almasy,et al. Endophenotypes as quantitative risk factors for psychiatric disease: rationale and study design. , 2001, American journal of medical genetics.
[23] K. Linton,et al. Structure of ABC transporters. , 2011, Essays in biochemistry.
[24] Eva Rönmark,et al. Health-related quality of life is related to COPD disease severity , 2005, Health and quality of life outcomes.
[25] Julie D Thompson,et al. Multiple Sequence Alignment Using ClustalW and ClustalX , 2003, Current protocols in bioinformatics.
[26] A. Sidow,et al. Physicochemical constraint violation by missense substitutions mediates impairment of protein function and disease severity. , 2005, Genome research.
[27] Michael R Knowles,et al. Genetic modifiers of lung disease in cystic fibrosis. , 2005, The New England journal of medicine.
[28] M. Corey,et al. Complex two-gene modulation of lung disease severity in children with cystic fibrosis. , 2008, The Journal of clinical investigation.
[29] Rappold,et al. Human Molecular Genetics , 1996, Nature Medicine.
[30] James T. L. Mah,et al. In silico SNP analysis and bioinformatics tools: a review of the state of the art to aid drug discovery. , 2011, Drug discovery today.
[31] M. Schwartz,et al. Association of mannose-binding lectin gene heterogeneity with severity of lung disease and survival in cystic fibrosis. , 1999, The Journal of clinical investigation.
[32] T. Scanlin,et al. Clinical evidence that V456A is a Cystic Fibrosis causing mutation in South Asians. , 2012, Journal of Cystic Fibrosis.
[33] S. Harvey,et al. Modeling the Conformational Changes Underlying Channel Opening in CFTR , 2013, PloS one.
[34] Andrew J. Grimm,et al. Interpreting missense variants: comparing computational methods in human disease genes CDKN2A, MLH1, MSH2, MECP2, and tyrosinase (TYR) , 2007, Human mutation.
[35] P. Waters,et al. Human phenylalanine hydroxylase mutations and hyperphenylalaninemia phenotypes: a metanalysis of genotype-phenotype correlations. , 1997, American journal of human genetics.
[36] M. Gill,et al. Functional genomics and schizophrenia: endophenotypes and mutant models. , 2007, The Psychiatric clinics of North America.
[37] Anavaj Sakuntabhai,et al. A variant in the CD209 promoter is associated with severity of dengue disease , 2005, Nature Genetics.
[38] Tom R. Gaunt,et al. Predicting the Functional, Molecular, and Phenotypic Consequences of Amino Acid Substitutions using Hidden Markov Models , 2012, Human mutation.